Celladon's advanced heart failure drug Mydicar has received breakthrough-therapy designation from the FDA and is the first gene therapy to receive the designation. The designation was based on data from a clinical trial that showed Mydicar reduced heart failure-related hospitalizations by 88% in patients receiving the highest dose of the drug.

Full Story:

Related Summaries